Anteris Technologies (ASX:AVR) secures utility patent for transcatheter heart valve

• Anteris (AVR) receives a utility patent from the United States Patent and Trademark Office for its novel DurAVR transcatheter heart valve (THV)
• DurAVR THV is a first-in-class biomimetic valve designed to mimic the performance of a healthy human heart valve
• AVR believes the unique aspects of the DurAVR design, including a single-piece valve construction, account for the “excellent” clinical results to date
• The patent expires on September 30, 2042
• AVR shares are up 3.02 per cent, trading at $23.18 at 11:20 am AEST

Anteris (AVR) has been issued a utility patent from the United States Patent and Trademark Office for its novel DurAVR transcatheter heart valve (THV).

DurAVR THV is a first-in-class biomimetic valve designed to mimic the performance of a healthy human heart valve.

The patent further confirms the development of a differentiated heart valve technology through AVRs single-piece, shaped-tissue design.

“The patent signifies the extraordinary work conducted by our team of engineers around the world responsible for the design of DurAVR THV,” AVR CEO Wayne Paterson said.

“The granting of this patent enhances the broad IP protection of DurAVR, strengthening our competitive position in the TAVR field.”

AVR believes the unique aspects of the DurAVR design, including a single-piece valve construction, account for the “excellent” clinical results to date.

The company is focused on developing next-generation healthcare technologies to help professionals deliver consistent life-changing outcomes.

The patent expires on September 30, 2042.

AVR shares were up 3.02 per cent, trading at $23.18 at 11:20 am AEST.